BrainXell enters into Global Licensing Agreement for induced Pluripotent Stem (iPS) Cell Patent Technology with iPS Academia Japan, Inc.
BrainXell Inc. (Madison, Wisconsin) and iPS Academia Japan, Inc. (Kyoto, Japan) have announced a global licensing agreement covering some of iPS Academia Japan’s induced pluripotent stem (iPS) cell patent portfolio. BrainXell may now develop and commercialize iPS-derived cells and offer related services to its customers under this non-exclusive agreement.
Madison, Wisconsin
BrainXell Inc. (Madison, Wisconsin) and iPS Academia Japan, Inc. (Kyoto, Japan) have announced a global licensing agreement covering some of iPS Academia Japan’s induced pluripotent stem (iPS) cell patent portfolio. BrainXell may now develop and commercialize iPS-derived cells and offer related services to its customers under this non-exclusive agreement. The iPS cell patent portfolio is mainly the result of work by Professor Shinya Yamanaka at the Center for iPS Cell Research and Application (CiRA) at Kyoto University. The terms of the agreement have not been disclosed.
“BrainXell is now enabled through this iPS ce

